United States Securities and Exchange Commission · EDGAR
Accession 0001610315-26-000005
Oxeia Biopharmaceuticals, Inc.
Nature of amendmentUpdate to Campaign Page
A
The Offering
as disclosed in this filing
Other (Series CF Preferred Stock)
$0.79
$20,000
$1,235,000
April 6, 2026
Expired 69 days ago
$0max $1,235,000
Target is 2% of the maximum. Over-subscriptions accepted.
B
Financial Condition
two fiscal years, as filed
Pre-revenueBurn decreasingDebt / assets 5322%2 employees
| Line item | Most recent FY | Prior FY | Δ |
|---|
| Revenue | 0 | 0 | — |
| Cost of goods sold | 0 | 0 | — |
| Net income | (1,219,002) | (1,939,043) | ▲ burn |
| Total assets | 233,373 | 211,440 | ▲ 10% |
| Cash & equivalents | 25,466 | 7,715 | ▲ 230% |
| Accounts receivable | 0 | 0 | — |
| Short-term debt | 8,520,223 | 7,812,933 | ▲ 9% |
| Long-term debt | 3,898,947 | 3,628,497 | ▲ 7% |
| Taxes paid | 0 | 0 | — |
Figures in USD as reported by the issuer. Securities offered in all 50 states.
C
Campaign Timeline
file 020-36726 · all filings under this campaign
Loading campaign history…